GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Total Equity

Oramed Pharmaceuticals (XTAE:ORMP) Total Equity : ₪606.41 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Total Equity?

Oramed Pharmaceuticals's total equity for the quarter that ended in Mar. 2024 was ₪606.41 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Oramed Pharmaceuticals Total Equity Historical Data

The historical data trend for Oramed Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Total Equity Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.96 120.31 426.36 553.12 596.07

Oramed Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 549.43 551.28 542.41 596.07 606.41

Oramed Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Oramed Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=807.05-210.985
=596.07

Oramed Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=745.213-138.799
=606.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Total Equity
Comparable Companies
Traded in Other Exchanges
ORMP:USA OJU1:Germany
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Website
https://www.oramed.com
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.